var data={"title":"Cefixime: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cefixime: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5839?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cefixime-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cefixime: Patient drug information&quot;</a> and <a href=\"topic.htm?path=cefixime-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cefixime: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147405\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Suprax</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147406\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Auro-Cefixime;</li>\n      <li>Suprax</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147443\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Cephalosporin (Third Generation)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147409\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Suprax 400 mg tablets have been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Susceptible infections:</b> Oral: 400 mg daily divided every 12 to 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gonococcal infection, uncomplicated infections of the cervix, urethra or rectum (rectum off-label use):</b> Oral: 400 mg as a single dose in combination with oral azithromycin as a single dose (CDC [Workowski 2015]). <b>Note:</b> CDC no longer recommends cefixime as a first-line agent (ceftriaxone is the preferred cephalosporin in combination with azithromycin); cefixime should only be used if ceftriaxone is unavailable. In addition, cefixime is not an option for the treatment of uncomplicated gonorrhea of the pharynx due to limited efficacy; if it must be used instead of ceftriaxone, a test-of-cure follow up should be performed 14 days after treatment (CDC [Workowski 2015]). In Canada, due to increased antimicrobial resistance, the Public Health Agency of Canada recommends 800 mg as a single dose (off-label dose) for treatment of uncomplicated gonococcal infections.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gonococcal infection, expedited partner therapy (off-label use):</b> Oral: 400 mg as a single dose in combination with oral azithromycin (CDC [Workowski 2015]). <b>Note:</b> To be used only for heterosexual partners with gonorrhea if health department partner-management strategies are impractical/unavailable and there is concern by the provider for the prompt evaluation and treatment of the partner; medication may be delivered to partner by patient, collaborating pharmacy, or disease investigation specialist as permitted by law; written materials to educate partners about their exposure to gonorrhea, importance of therapy, and when to seek clinical evaluation for adverse reactions/complications must also be provided with the medication (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>S. pyogenes</i></b>\n      <b> infections:</b> Oral: 400 mg daily divided every 12 to 24 hours for &ge;10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Typhoid fever (off-label use):</b> Oral: 15 to 20 mg/kg/day in 2 divided doses for 7 to 14 days (Parry 2002; WHO 2003)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147427\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=cefixime-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cefixime: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Suprax 400 mg tablets have been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Susceptible infections:</b> Oral: <b>Note:</b> Otitis media should be treated using the chewable tablets or suspension <b>only</b>. Chewable tablets and suspension achieve higher peak blood levels compared to an equivalent dose using the tablet or capsule.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;6 months and &le;45 kg: 8 mg/kg/day divided every 12 to 24 hours (maximum: 400 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dosing recommendations based on body weight (doses are rounded for use of oral suspension or chewable tablet):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">5 to &lt;7.6 kg: 50 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">7.6 to &lt;10.1 kg: 80 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">10.1 to &lt;12.6 kg: 100 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">12.6 to &lt;20.6 kg: 150 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">20.6 to &lt;28.1 kg: 200 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">28.1 to &lt;33.1 kg: 250 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">33.1 to &lt;40.1 kg: 300 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">40.1 to &le;45 kg: 350 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;45 kg or &gt;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Acute bacterial rhinosinusitis (off-label use):</b> Oral: 8 mg/kg/day divided every 12 hours with concomitant clindamycin for 10 to 14 days. <b>Note:</b> Recommended in patients with non-type I penicillin allergy, after failure of initial therapy or in patients at risk for antibiotic resistance (eg, daycare attendance, age &lt;2 years, recent hospitalization, antibiotic use within the past month) (Chow 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gonococcal infection, uncomplicated infections of the cervix, urethra or rectum (rectum off-label use):</b> Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gonococcal infection, expedited partner therapy (off-label use):</b> Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>S. pyogenes</i></b>\n      <b> infections:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;6 months and &le;45 kg: 8 mg/kg/day divided every 12 to 24 hours for &ge;10 days (maximum: 400 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;45 kg or &gt;12 years and Adolescents: 400 mg daily divided every 12 to 24 hours for &ge;10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Typhoid fever (off-label use):</b> Oral: 15 to 20 mg/kg/day divided every 12 hours for 7 to 14 days; maximum 400 mg daily (Girgis 1995; Stephens 2002)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147410\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147411\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">CrCl &ge;60 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">CrCl 21 to 59 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Chewable tablet, tablet: Not recommended</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/5 mL, 200 mg/5 mL, or 500 mg/5 mL suspension: 260 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">CrCl &le;20 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Chewable tablet, tablet: 200 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/5 mL suspension: 172 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/5 mL suspension: 176 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/5 mL suspension: 180 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Intermittent hemodialysis (not significantly removed by hemodialysis):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Chewable tablet, tablet: Not recommended</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Suspension: 260 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">CAPD (not significantly removed by peritoneal dialysis):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Chewable tablet, tablet: 200 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/5 mL suspension: 172 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/5 mL suspension: 176 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/5 mL suspension: 180 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Canadian labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &ge;40 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl  20 to &lt;40 mL/minute: Administer 75% of normal daily dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl  &lt;20 mL/minute: Administer 50% of normal daily dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20453038\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147381\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Suprax: 400 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Suprax: 100 mg/5 mL (50 mL) [strawberry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Suprax: 200 mg/5 mL (50 mL, 75 mL); 500 mg/5 mL (10 mL, 20 mL) [contains sodium benzoate; strawberry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg/5 mL (50 mL); 200 mg/5 mL (50 mL, 75 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Suprax: 400 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Chewable, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Suprax: 100 mg, 200 mg [contains aspartame, fd&amp;c red #40 aluminum lake; tutti-frutti flavor]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147365\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28606289\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Suprax 400 mg tablets have been discontinued in the US for more than 1 year.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147385\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">May be administered with or without food. Shake oral suspension well before use. Chewable tablets must be chewed or crushed before swallowing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147384\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Treatment of uncomplicated urinary tract infections (due to <i>Escherichia coli</i> and <i>Proteus mirabilis</i>), otitis media (due to <i>Haemophilus influenzae, Moraxella catarrhalis,</i> and <i>Streptococcus pyogenes</i>), pharyngitis and tonsillitis (due to <i>Streptococcus pyogenes</i>), acute exacerbations of chronic bronchitis (due to <i>Streptococcus pneumoniae</i> and <i>Haemophilus influenzae</i>); uncomplicated cervical/urethral gonorrhea (due to<i> N. gonorrhoeae</i> [penicillinase- and nonpenicillinase-producing])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Note:</b> Due to concerns of resistance, the CDC no longer recommends use of cefixime as a first-line regimen in the treatment of uncomplicated gonorrhea in the US; ceftriaxone is the preferred cephalosporin in combination with azithromycin (CDC 2012; CDC [Workowski 2015]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475329\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute bacterial rhinosinusitis; Gonococcal infection, expedited partner therapy; Gonococcal, uncomplicated  infection of the rectum; Typhoid fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147450\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cefixime may be confused with cefepime </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Suprax may be confused with Sporanox</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cefiton: Brand name for cefixime [Portugal] may be confused with Ceftim brand name for ceftazidime [Portugal]; Ceftime brand name for ceftazidime [Thailand]; Ceftin brand name for cefuroxime [US, Canada]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147372\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%: Gastrointestinal: Diarrhea (16%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">2% to 10%: Gastrointestinal: Abdominal pain, nausea, dyspepsia, flatulence, loose stools </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;2%: Acute renal failure, anaphylactoid reaction, anaphylaxis, angioedema, candidiasis, dizziness, drug fever, eosinophilia, erythema multiforme, facial edema, fever, headache, hepatitis, hyperbilirubinemia, increased blood urea nitrogen, increased serum creatinine, increased serum transaminases, jaundice, leukopenia, neutropenia, prolonged prothrombin time, pruritus, pseudomembranous colitis, seizure, serum sickness-like reaction, skin rash, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis, urticaria, vaginitis, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147388\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cefixime, any component of the formulation, or other cephalosporins or penicillins</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147369\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic reactions: Severe cutaneous reactions (eg, toxic epidermal necrolysis, Stevens-Johnson syndrome, drug rash with eosinophilia and systemic symptoms [DRESS]) have been reported. If a reaction occurs, discontinue and institute supportive therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemolytic anemia: Immune-mediated hemolytic anemia (including fatalities) have been reported. Monitor patient (including hematologic parameters and drug-induced antibody testing when clinically appropriate) during and for 2 to 3 weeks after therapy. If hemolytic anemia occurs during therapy, discontinue use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity and anaphylaxis have been reported in patients receiving beta-lactam drugs. Use caution in patients with a history of hypersensitivity to cephalosporins, penicillins, or other beta-lactams. If administered to penicillin-sensitive patients, use with caution and discontinue use if allergic reaction occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal failure: May cause acute renal failure including tubulointerstitial nephritis. If renal failure occurs, discontinue and initiate appropriate supportive therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; may increase the risk of seizures if dosage not reduced; modify dosage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disease: Use with caution in patients with a history of gastrointestinal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemolytic anemia: Should not be administered to patients with a history of cephalosporin-associated hemolytic anemia; recurrence of hemolysis is more severe.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Phenylalanine: Chewable tablets contain phenylalanine; avoid use or use with caution in patients with phenylketonuria (PKU).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298989\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147374\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9216&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147401\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food delays cefixime absorption. Management: May administer with or without food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147377\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5951284\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Teratogenic effects were not observed in animal reproduction studies. Cefixime crosses the placenta and can be detected in the amniotic fluid (Ozy&uuml;nc&uuml; 2010). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147391\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if cefixime is excreted in breast milk. The manufacturer recommends that consideration be given to discontinuing nursing temporarily during treatment. If present in breast milk, nondose-related effects could include modification of bowel flora.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147392\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Chewable tablets contain phenylalanine; avoid use or use with caution in patients with phenylketonuria (PKU).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147379\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Renal function; with prolonged therapy, monitor renal and hepatic function periodically. Observe for signs and symptoms of anaphylaxis during first dose. When used as part of alternative treatment for gonococcal infection, test-of-cure 7 days after dose (CDC 2012). Monitor hematologic parameters and drug-induced antibody testing (when clinically appropriate) during and for 2 to 3 weeks after therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147368\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs); which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147387\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">\n      <b>Note:</b> Chewable tablets and oral suspension are bioequivalent. However, oral suspension and tablet (nonchewable)/capsule formulations are <b>not</b> considered bioequivalent (oral suspension AUC ~10% to 25% greater compared with tablet after doses of 100-400 mg in normal adult volunteers).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">Absorption: 40% to 50%; <b>Note:</b> Capsule AUC reduced by ~15% and C<sub>max</sub> by ~25% when taken with food.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely throughout the body and reaches therapeutic concentration in most tissues and body fluids, including synovial, pericardial, pleural, peritoneal; bile, sputum, and urine; bone, myocardium, gallbladder, and skin and soft tissue </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 65% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Normal renal function: 3 to 4 hours;  Moderate impairment (CrCl  20 to 40 mL/minute): 6.4 hours; Renal failure: Up to 11.5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Tablet, suspension: 2 to 6 hours; Capsule: 3 to 8 hours; Delayed with food</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (50% of absorbed dose as active drug); feces (10%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6133204\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Suprax Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (10): $276.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (Suprax Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (10): $234.35</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (10): $468.71</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Cefixime Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/5 mL (50 mL): $222.69</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/5 mL (50 mL): $445.39</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Suprax Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/5 mL (50 mL): $272.21</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/5 mL (50 mL): $544.42</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/5 mL (10 mL): $272.21</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147393\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aerocef (AT);</li>\n      <li>Anfix (ID);</li>\n      <li>Bicebid (VN);</li>\n      <li>Cavlis (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Cefarox (ID);</li>\n      <li>Cefexin (HR);</li>\n      <li>Cefiac (BD);</li>\n      <li>Cefiget (VN);</li>\n      <li>Cefim (BD, ET, KW);</li>\n      <li>Cefimark (VN);</li>\n      <li>Cefimed (ET);</li>\n      <li>Cefirax (KR);</li>\n      <li>Cefix (AE, BH, CY, EG, ET, IQ, IR, JO, KR, KW, LB, LY, MY, OM, SA, SY, YE);</li>\n      <li>Cefixmycin (PH, TW);</li>\n      <li>Cefspan (CN, ID, JP, PK, TH, TW, VN);</li>\n      <li>Ceftoral (GR);</li>\n      <li>Cephoral (CH, DE);</li>\n      <li>Cerafix (ID);</li>\n      <li>Cexim (TW);</li>\n      <li>Cexima (PY);</li>\n      <li>Chifix (LK);</li>\n      <li>Cifacure (PH);</li>\n      <li>Cifex (TR);</li>\n      <li>Denvar (CR, DO, ES, GT, HN, MX, NI, PA, SV);</li>\n      <li>Devoxim (CO);</li>\n      <li>Edixim (HR);</li>\n      <li>Eficef (RO);</li>\n      <li>Fix A (BD);</li>\n      <li>Fix-A (PH);</li>\n      <li>Fixcef (PH);</li>\n      <li>Fixef (ID);</li>\n      <li>Fixim (CR, DO, GT, HN, LB, NI, NL, PA, SV);</li>\n      <li>Fixime (ZA);</li>\n      <li>Fixiphar (ID);</li>\n      <li>Fixitil-T (LK);</li>\n      <li>Fixx (IN);</li>\n      <li>Flamifiks (UA);</li>\n      <li>Hafixim (VN);</li>\n      <li>Ikzym (UA);</li>\n      <li>Ixime (AE, MY);</li>\n      <li>Lanfix (ID);</li>\n      <li>Longacef (VE);</li>\n      <li>Lopraks (UA);</li>\n      <li>Magnacef (AE, BH, JO, LB, QA, SA);</li>\n      <li>Maxicef (PE);</li>\n      <li>Maxpro (ID);</li>\n      <li>Minixime (MY);</li>\n      <li>Mycefix (PH);</li>\n      <li>Neocef (PT);</li>\n      <li>Novacef (AR);</li>\n      <li>Oralcef (PY);</li>\n      <li>Oroken (FR);</li>\n      <li>Pancef (BG);</li>\n      <li>Savecef (LK);</li>\n      <li>Septipan (PH);</li>\n      <li>Simfix (ID);</li>\n      <li>Sixime (TH);</li>\n      <li>Sofix (ID);</li>\n      <li>Sortsef (UA);</li>\n      <li>Spaxim (ID);</li>\n      <li>Starcef (ID);</li>\n      <li>Supracef (FI);</li>\n      <li>Supran (IL);</li>\n      <li>Suprax (AE, BB, BH, CZ, DE, EG, GB, HU, IE, IT, JO, KR, KW, LB, QA, RU, SA, SK, TR);</li>\n      <li>Surixime (PH);</li>\n      <li>Tadix (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Taxocef-O (PH);</li>\n      <li>Tergecef (PH);</li>\n      <li>Tocef (ID);</li>\n      <li>Topcef (LK);</li>\n      <li>Tricef (BD, CL, MT, PT, SE, TR);</li>\n      <li>Ultraxime (PH);</li>\n      <li>Urticef (ID);</li>\n      <li>Vineks (UA);</li>\n      <li>Vipime (LK);</li>\n      <li>Winex (AE, KW, LB, QA, SA);</li>\n      <li>Xifia (RO);</li>\n      <li>Yafix (ID);</li>\n      <li>Zefral (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;1998 Guidelines for the Treatment of Sexually Transmitted Diseases. Centers for Disease Control and Prevention,&rdquo; <i>MMWR Recomm Rep</i>, 1998, 47(RR-1):1-111.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ashkenazi S, Amir J, Waisman Y, et al, &ldquo;A Randomized, Double-Blind Study Comparing Cefixime and Trimethoprim-Sulfamethoxazole in the Treatment of Childhood Shigellosis,&rdquo; <i>J Pediatr</i>, 1993, 123(5):817-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-drug-information/abstract-text/8229498/pubmed\" target=\"_blank\" id=\"8229498\">8229498</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al. &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: Oral Cephalosporins No Longer a Recommended Treatment for Gonococcal Infections&rdquo;, <i>MMWR Morb Mortal Wkly Rep</i>, 2012, 61(31):590-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-drug-information/abstract-text/22874837/pubmed\" target=\"_blank\" id=\"22874837\">22874837</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow AW, Benninger MS, Brook I, et al, &ldquo;IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,&rdquo; <i>Clin Infect Dis</i>, 2012, 54(8):e72-112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-drug-information/abstract-text/22438350/pubmed\" target=\"_blank\" id=\"22438350\">22438350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daschner M. Drug dosage in children with reduced renal function. <i>Pediatr Nephrol</i>. 2005;20:1675-1686.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-drug-information/abstract-text/16133064/pubmed\" target=\"_blank\" id=\"16133064\">16133064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dhib M, Moulin B, Leroy A, et al. Relationship between renal function and disposition of oral cefixime. <i>Eur J Clin Pharmacol</i>. 1991;41:579-583.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-drug-information/abstract-text/1815970/pubmed\" target=\"_blank\" id=\"1815970\">1815970</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Donowitz GR and Mandell GL, &ldquo;Beta-Lactam Antibiotics,&rdquo; <i>N Engl J Med</i>, 1988, 318(7):419-26 and 318(8):490-500.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-drug-information/abstract-text/3277054/pubmed\" target=\"_blank\" id=\"3277054\">3277054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Faulkner RD, Bohaycheck W, Lanc RA, et al, &ldquo;Pharmacokinetic of Cefixime in Young and Elderly,&rdquo; <i>J Antimicrob Chemother</i>, 1988, 21(6):787-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-drug-information/abstract-text/3410802/pubmed\" target=\"_blank\" id=\"3410802\">3410802</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7567290\"></a>Girgis NI, Sultan Y, Hammad O, et al, &quot;Comparison of the Efficacy, Safety and Cost of Cefixime, Ceftriaxone and Aztreonam in the Treatment of Multidrug-Resistant <i>Salmonella typhi</i> Septicemia in Children,&quot; <i>Pediatr Infect Dis J</i>, 1995, 14(7):603-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-drug-information/abstract-text/7567290/pubmed\" target=\"_blank\" id=\"7567290\">7567290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson CE, Carlin SA, Super DM, et al, &ldquo;Cefixime Compared With Amoxicillin for Treatment of Acute Otitis Media,&rdquo; <i>J Pediatr</i>, 1991, 119(1):117-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-drug-information/abstract-text/1906097/pubmed\" target=\"_blank\" id=\"1906097\">1906097</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine WC, Berg AO, Johnson RE, et al, &ldquo;Development of Sexually Transmitted Diseases Treatment Guidelines, 1993. New Methods, Recommendations, and Research Priorities,&rdquo; STD Treatment Guidelines Project Team and Consultants, <i>Sex Transm Dis</i>, 1994, 21(2 Suppl):96-101.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Markham A and Brogden RN, &ldquo;Cefixime. A Review of Its Therapeutic Efficacy in Lower Respiratory Tract Infections,&rdquo; <i>Drugs</i>, 1995, 49(6):1007-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-drug-information/abstract-text/7641600/pubmed\" target=\"_blank\" id=\"7641600\">7641600</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marshall WF and Blair JE, &ldquo;The Cephalosporins,&rdquo; <i>Mayo Clin Proc</i>, 1999, 74(2):187-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-drug-information/abstract-text/10069359/pubmed\" target=\"_blank\" id=\"10069359\">10069359</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ozy&uuml;nc&uuml; O, Beksac MS, Nemutlu E, et al, &quot;Maternal Blood and Amniotic Fluid Levels of Moxifloxacin, Levofloxacin and Cefixime,&quot; <i>J Obstet Gynaecol Res</i>, 2010, 36(3):484-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-drug-information/abstract-text/20598025/pubmed\" target=\"_blank\" id=\"20598025\">20598025</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Public Health Agency of Canada. Canadian Guidelines on Sexually Transmitted Infections. https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines.html. Accessed August 8, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12456854\"></a>Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. <i>N Engl J Med</i>. 2002;347(22):1770-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-drug-information/abstract-text/12456854/pubmed\" target=\"_blank\" id=\"12456854\">12456854</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schatz BS, Karavokiros KT, Taeubel MA, et al, &ldquo;Comparison of Cefprozil, Cefpodoxime Proxetil, Loracarbef, Cefixime, and Ceftibuten,&rdquo; <i>Ann Pharmacother</i>, 1996, 30(3):258-68.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-drug-information/abstract-text/8833562/pubmed\" target=\"_blank\" id=\"8833562\">8833562</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith GH, &ldquo;Oral Cephalosporins in Perspective,&rdquo; <i>DICP</i>, 1990, 24(1):45-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-drug-information/abstract-text/2405586/pubmed\" target=\"_blank\" id=\"2405586\">2405586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stephens I and Levine MM, &quot;Management of Typhoid Fever in Children,&quot; <i>Pediatr Infect Dis J</i>, 2002, 21(2):157-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-drug-information/abstract-text/11840084/pubmed\" target=\"_blank\" id=\"11840084\">11840084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Suprax (cefixime) [prescribing information]. Baltimore, MD: Lupin Pharmaceuticals Inc; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Suprax (cefixime) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO), &ldquo;Background Document: The Diagnosis, Treatment and Prevention of Typhoid Fever,&rdquo; May 2003. Available at http://apps.who.int/iris/bitstream/10665/68122/1/WHO_V-B_03.07_eng.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefixime-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9216 Version 168.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F147405\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F147406\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F147443\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F147409\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F147427\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F147410\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F147411\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F20453038\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F147381\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F147365\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F28606289\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F147385\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F147384\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475329\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F147450\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F147372\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F147388\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F147369\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298989\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F147374\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F147401\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F147377\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5951284\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F147391\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F147392\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F147379\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F147368\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F147387\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F6133204\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F147393\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9216|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cefixime-patient-drug-information\" class=\"drug drug_patient\">Cefixime: Patient drug information</a></li><li><a href=\"topic.htm?path=cefixime-pediatric-drug-information\" class=\"drug drug_pediatric\">Cefixime: Pediatric drug information</a></li></ul></div></div>","javascript":null}